Status:
COMPLETED
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
Lead Sponsor:
Neurognostics
Conditions:
Relapsing-Remitting Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine if medication designed to improve memory will help patients with Multiple Sclerosis (MS) who are experiencing memory problems using fMRI to track brain activi...
Detailed Description
Donepezil HCI (Aricept®) is an FDA-approved drug now used to enhance memory in patients with Alzheimer's disease. The aim of this project is to examine the effects of Donepezil HCI (Aricept®) on memor...
Eligibility Criteria
Inclusion
- Between 18 and 65 years of age and experiencing some forgetfulness
- Diagnosed with MS, currently taking Rebif® and experiencing mild memory problems
- Participants will have stable medication dosages 1 month prior to testing
- With no past or present neurological disorders (e.g. head trauma, seizures, encephalitis, stroke) except MS
- With no known medical illnesses (e.g. diabetes, uncontrolled hypertension, arthritis)
- With no psychiatric illness
- With no current substance abuse
- Females should not be pregnant or nursing
- With no metallic devices in the body or claustrophobia
Exclusion
- Previous history of CNS disturbance other than MS
- Severe motor or visual impairment that might interfere with the cognitive activation tasks
- Prescribed psychoactive medications
- Memory deficits caused by other significant neurological disease or psychiatric disorder
- Active malignancy within one year of study participation
- Known human immunodeficiency virus (HIV)
- Current diagnosis of unstable glaucoma; history of myocardial infarction
- Symptomatic Coronary Artery Disease within the last 12 months or evidence of ongoing ischemia or uncontrolled atrial or ventricular arrhythmias as shown by ECG; poorly controlled or labile hypertension
- History of epilepsy or other seizure disorder within the past 12 months
- Allergy or hypersensitivity to amphetamines or other sympathomimetic amines
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00315367
Start Date
September 1 2004
End Date
October 1 2007
Last Update
October 16 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226